Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

BACKGROUND: Acquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent advanced treatment options such as liposomal formulations, proteasome inhibitors, immunomodulatory drugs, myeloma-targeted antibodies, and histone deacetylase inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Joel G., Dawson, Jana L., Grant, Steven, Shain, Kenneth H., Dalton, William S., Dai, Yun, Meads, Mark, Baz, Rachid, Kauffman, Michael, Shacham, Sharon, Sullivan, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997728/
https://www.ncbi.nlm.nih.gov/pubmed/27557643
http://dx.doi.org/10.1186/s13045-016-0304-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997728/
https://www.ncbi.nlm.nih.gov/pubmed/27557643
http://dx.doi.org/10.1186/s13045-016-0304-z

Ejemplares similares